width=The laboratory of Stephen Jackson, PhD at the University of Cambridge in England has used CRISPR/Cas gene editing technology in cells to find genes that, when altered, compensate for the lack of the ATM protein. Now, with new funding from the A-T Children’s Project as well as Action for A-T, a UK-based non-profit organization, Dr. Jackson’s team will explore how targeting those genes might be translated into therapies that would make A-T less severe for patients.

In addition, Dr. Jackson’s laboratory has been studying a unique patient who lacks detectable levels of the ATM protein and should have the typical presentation of A-T but instead has remarkably milder symptoms. The lab has generated induced pluripotent stem cells from this extraordinary person and is now looking for genetic and environmental factors that may be responsible for reducing the severity of symptoms and the rate of disease progression.

Dr. Jackson’s two approaches may lead to new treatment opportunities for A-T.

Oops! We could not locate your form.

Related News

May 21 @ 5:41 am

Shining a Light on A-T at the IlluminATion Ball

The A-TCP is hosting IlluminATion: A BioPharma Leadership Ball on May 11 in Boston to shine a light

more
May 21 @ 5:41 am

NEAT Study – Phase 3 Clinical Trial of EryDex, a Low-Dose Steroid

Quince Therapeutics is advancing a phase 3 clinical trial to evaluate EryDex, a potential new treatment for ataxia-telangiectasia

more
May 21 @ 5:41 am

Measles Prevention in A-T: Recommendations from Dr. Lederman

Dr. Lederman of the A-T Clinical Center provides recommendations to keep people with A-T from catching measles.

more
May 21 @ 5:41 am

Looking Forward to Research Advances in 2024

As 2023 is wrapping up, we want to thank all of you who support the A-T Children’s Project

more